SI
Sucrase-isomaltase, intestinal [Cleaved into: Sucrase
As of the edition of 20 October 2026, SI (sucrase-isomaltase, intestinal [Cleaved into: Sucrase, UniProt P14410) has 2 drugs tested at it and 4 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P14410
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Infections; Nutrition and metabolism; Hormones; Digestive system; Immune system; Urinary and reproductive; Heart and blood vessels
- Registered trials of its drugs
- 17
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Voglibose | Marketed | Phase 4 | none listed |
| Celgosivir | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Sanofi | Route A |
| BioWest Therapeutics | Route A |
The other 2 companies at SI
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at SI, ranked, with the facts behind eachRequest access. Nothing is shown until you do.